2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

          The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline.

            This article is part of a combined publication that expresses the current view of the European Society of Gastrointestinal Endoscopy about endoscopic biliary stenting. The present Clinical Guideline describes short-term and long-term results of biliary stenting depending on indications and stent models; it makes recommendations on when, how, and with which stent to perform biliary drainage in most common clinical settings, including in patients with a potentially resectable malignant biliary obstruction and in those who require palliative drainage of common bile duct or hilar strictures. Treatment of benign conditions (strictures related to chronic pancreatitis, liver transplantation, or cholecystectomy, and leaks and failed biliary stone extraction) and management of complications (including stent revision) are also discussed. A two-page executive summary of evidence statements and recommendations is provided. A separate Technology Review describes the models of biliary stents available and the stenting techniques, including advanced techniques such as insertion of multiple plastic stents, drainage of hilar strictures, retrieval of migrated stents and combined stenting in malignant biliary and duodenal obstructions.The target readership for the Clinical Guideline mostly includes digestive endoscopists, gastroenterologists, oncologists, radiologists, internists, and surgeons while the Technology Review should be most useful to endoscopists who perform biliary drainage. © Georg Thieme Verlag KG Stuttgart · New York.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.

              To assess the impact of postoperative complications on the receipt of adjuvant chemotherapy.
                Bookmark

                Author and article information

                Journal
                Acta Oncologica
                Acta Oncologica
                Informa UK Limited
                0284-186X
                1651-226X
                August 13 2018
                December 02 2018
                September 28 2018
                December 02 2018
                : 57
                : 12
                : 1655-1662
                Affiliations
                [1 ] Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands;
                [2 ] Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands;
                [3 ] Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands;
                [4 ] Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;
                [5 ] Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands;
                [6 ] Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands;
                [7 ] Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, the Netherlands;
                [8 ] Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands
                Article
                10.1080/0284186X.2018.1518593
                30264642
                0628c40d-d49e-433c-8e8c-d7203aae43ef
                © 2018
                History

                Comments

                Comment on this article